Dec 13, 2016 | 2016, Past Events
Philogen S.p.A. announces participation in the “Antibody Engineering & Therapeutics Meeting”, 11 – 15 December 2016, San Diego, CANov 7, 2016 | 2016, Past Events
Philogen S.p.A. and its fully owned subsidiary Philochem AG, announce their participation to the “3rd ShanghaiTech-SIAIS BioForum”, 7-10 November 2016, Shanghai, China PHILOGEN S.P.A ANNOUNCES PARTICIPATION IN THE “3RD SHANGHAITECH-SIAIS BIOFORUM”, 7-10...Nov 1, 2016 | 2016, Past Events
Philogen S.p.A. announces participation in the “World Immunotherapy Congress 2016”, 14 – 16 November 2016, Basel, Switzerland PHILOGEN S.P.A. ANNOUNCES PARTICIPATIO IN THE “WORLD IMMUNOTHERAPY CONGRESS 2016”, 14 – 16 NOVEMBER 2016,...Oct 31, 2016 | 2016, Past Events
Philogen S.p.A announces participation in “PEGS Europe – Protein & Antibody Engineering Summit” , 31 October – 4 November 2016, Lisbon, Portugal PHILOGEN S.P.A ANNOUNCES PARTICIPATION IN “PEGS EUROPE – PROTEIN & ANTIBODY ENGINEERING...Oct 28, 2016 | 2016, Press Releases, Scientific
Philogen S.p.A. announced that the European Commission (EC) has granted Orphan Drug Designation to L19TNF for the treatment of soft-tissue sarcoma. PHILOGEN S.P.A. RECEIVES ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF SOFT-TISSUE SARCOMAAug 11, 2016 | 2016, Past Events
Philogen S.p.A. announces participation in “XXIV EFMC INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY”, 28 August – 1 September 2016, Manchester, UK PHILOGEN S.P.A. ANNOUNCES PARTICIPATION IN “XXIV EFMC INTERNATIONAL SYMPOSIUM ON MEDICINAL CHEMISTRY”...
Recent Comments